BioSight
Companies
4D Molecular Therapeutics, Inc. logo

FDMT

NASDAQEMERYVILLE, CA
4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics develops gene therapy treatments using a proprietary platform technology. The company is advancing multiple clinical-stage product candidates (4D-150, 4D-175, 4D-710, and 4D-725) and has additional programs in lead optimization, though the specific therapeutic areas are not detailed in this excerpt. 4D is dependent on securing funding to continue development and eventual commercialization of these candidates.

Price history not yet available for FDMT.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar